What top creators are saying about Bristol-Myers Squibb Company(BMY)

The speaker said the company appeared to be executing well and cited growth across several medicines, while noting that Reblozyl's outcome was disappointing relative to expectations.

The company is partnering with Anthropic to apply AI to bottlenecks and planning in early-stage clinical trials, but no financial impact or measurable results are established.

Mentioned among companies providing customer testimonials for Anthropic; no investment commentary was provided.

Mentioned as a company providing a customer testimonial for Anthropic; no investment view was offered.

Mentioned as the source of drug-candidate rights acquired for development; the example was not presented as an endorsement of its stock.

Cited as an example of a large pharmaceutical company selling or licensing underused drug assets; the comments concerned the licensing market, not the stock's outlook.

The speaker questioned a reported dose-response pattern in a collaborative treatment and separately said he did not know why the stock was down that day.

A speaker had generally been bearish but was reviewing the pipeline. The discussion highlighted mixed assessments of several programs, with some limitations noted and CAR-T described as an area where the company was doing reasonably well.

A speaker said they were looking at Bristol Myers, referred to as BMI in the transcript, but provided no thesis or catalyst.

The host was generally bearish on the company and cautious about several pipeline assets, though he expressed interest in its EGFR/HER3 ADC and CAR-T program.

The host questioned why shares were falling and expressed concern about clinical results from a BioNTech collaboration, but did not establish their impact on Bristol Myers' value.

Portfolio described as a 'disaster' with aging franchises facing revenue cliffs; identified as a potential short opportunity.

Facing a major patent cliff for Eliquis, high debt load, and underperforming drug launches.

Benefits from a highly favorable regulatory environment where the FDA is reducing barriers and accelerating approvals for cell and gene therapies, including CAR-T.

Cited as a large-cap pharma company likely to be an acquirer, but the investment thesis favors owning the smaller biotech targets instead.

Bullish view as the stock has broken a long-term downtrend. At $54, there is potential for it to run towards its prior highs around $63.

The host calls this a 'strong pass,' advising against buying the company due to a series of drug pipeline disappointments and the inherent volatility of the industry.

Mentioned as a well-performing stock in the healthcare sector, which is attracting investor attention as a defensive play offering 'bond-like dividend yields with potentially equity-like upside'.

Stock is down 17% due to underperformance in the pharma sector caused by political pressure to lower U.S. drug prices.